Table 2 Antibody titer levels of 90% protection of SARS-CoV-2 infection (i.e., 10% relative risk) during the study period
Overall cohort | Subsampling | |||
|---|---|---|---|---|
Anti-S (BAU/mL) Median (95% CredI) | Anti-N (COI) Median (95% CredI) | BA.5 NT Median (95% CredI) | Anti-N (COI) Median (95% CredI) | |
Hybrid and Non-hybrid | ||||
Symptomatic and Asymptomatic | >523,000 | 19.9 (18.2–21.9) | >3620 | 12.3 (8.5–18.9) |
Symptomatic | 10,209 (6966–14,997) | <1.0 | 10 (3–38) | <1.0 |
Asymptomatic | >523,000 | 17.2 (15.7–18.7) | >3620 | 11.7 (7.9–17.7) |
Hybrid | ||||
Symptomatic and Asymptomatic | Undetermined | 18.1 (16.6–18.1) | Undetermined | 10.2 (6.2–20.2) |
